# A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

> **NCT04866836** · PHASE2 · TERMINATED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 20 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Radiotherapy

## Key facts

- **NCT ID:** NCT04866836
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The study was prematurely terminated due to difficulties in recruitment.
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866836, "A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04866836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*